Figure 1.

Psoriasis Area and Severity Index 75 at week 12 across three Phase III studies^a with secukinumab 300 mg in patients with moderate-to-severe psoriasis. *P < 0.001, **P < 0.0001, ^aComparator: Placebo in ERASURE, Etanercept in FIXTURE and ustekinumab in CLEAR. ERASURE: Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis; FIXTURE: Full Year Investigative Examination of Secukinumab versus Etanercept using Two Dosing Regimens to Determine Efficacy in Psoriasis, CLEAR: Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab